Today news
About the same in other media
UK firm to trial T-cell Covid vaccine that could give longer immunity
Reading now: 654
An Oxfordshire-based company will soon start clinical trials of a second-generation vaccine against Covid-19, an easy-to-administer skin patch that uses T-cells to kill infected cells and could offer longer-lasting immunity than current vaccines.
Emergex was set up in Abingdon in 2016 to develop T-cell vaccines, the brainchild of Prof Thomas Rademacher, the firm’s chief executive and professor emeritus of molecular medicine at the University College London medical school.
The vaccines prime T-cells to remove infected cells from the body quickly after infection, thus preventing viral replication and disease. While the antibodies produced by the current Covid vaccines stick to the virus and stop it infecting cells, T-cells find and destroy
Read more on theguardian.comAbout this in other media
US facial recognition firm faces £17m UK fine for ‘serious breaches’ theguardian.com /3 years ago
Collapse of UK energy firms could cost each household extra £120 theguardian.com /3 years ago
Travel firms scramble to rearrange holidays amid new Covid measures theguardian.com /3 years ago
Show more
The website finance-news.co. is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
